Role of an E-cigarette on Smoking Displacement in Smokers With Schizophrenia

Completed

Conditions studied: Schizophrenia and Related Disorders

In brief

It is well established in the scientific literature that people with schizophrenia smoke tobacco cigarettes at rates up to three times that of the general population, relapse more frequently, and die an average of 25 years earlier from cigarette smoking and other life-style attributable illnesses. Electronic cigarettes (e-cigarettes) are becoming increasingly popular with smokers worldwide and new research suggests that e-cigarettes are appealing to smokers with schizophrenia. There is a paucity of research focused on the experience of smokers with schizophrenia who decide to try an e-cigarette. A well-designed prospective-observational study is needed to learn more about the influence of e-cigarette use on cigarette smoking behavior and mental and physical health among smokers with schizophrenia. In response, the investigators have designed a study titled, Role of an electronic cigarette on smoking displacement in smokers with schizophrenia: A prospective 3-month pilot study (SchizEcig).

Key facts

Study ID

NCT03075202

Run by

Weill Medical College of Cornell University

People needed

1

Starts

2017-03-03

Expected to finish

2018-12-24

Last updated by the study team

2019-01-11

Who can join

Age: 21 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of a schizophrenia spectrum disorder
• Non-hospitalized persons
• Regular smokers who report smoking 20 or more cigarettes per day who have smoked at least 100 cigarettes in their lifetime, and are not intending to reduce or quit
• Has agreed to try an e-cigarette
• Must be able to provide written informed consent
• Must be able to read, write and communicate in English proficiently
• Must have access to a computer with internet
• Must have the ability to work a computer and navigate the internet easily

You may not qualify if…

• Non-smokers Persons without a schizophrenia spectrum disorder diagnosis
• Hospitalized persons
• Cardio vascular disease
• Respiratory disease
• Use of smokeless tobacco or any other tobacco products besides cigarettes.
• Use of nicotine replacement therapy or other smoking cessation pharmaco-therapies within the last 3 months
• Pregnancy or breastfeeding

Where it is running

• Clinical and Translational Science Center, Weill Cornell Medicine, 525 E 68th Street, F-260 — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.